← All indications
Severe Acute Respiratory Syndrome
A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.
Drugs by status
Approved for this indication (1)
Phase 4 trials (13)
Phase 3 trials (48)
- metformin
- montelukast
- edoxaban
- methylprednisolone
- artemisinin
- bacille calmette-guerin
- dornase alfa
- fludrocortisone
- proxalutamide
- hydroxychloroquine
- ritonavir
- vitamin c
- atazanavir
- colchicine
- fostamatinib
- streptokinase
- lopinavir
- sivelestat
- bevacizumab
- angiotensin 1-7
- tocilizumab
- enoxaparin
- allogeneic adipose derived mesenchymal stem cell
- boswellia serrata
- curcumin
- multistem
- azithromycin
- chloroquine
- hypochlorous acid
- oxygen
- +18 more
Phase 2 trials (64)
- vitamin d3
- xanthohumol
- aminolevulinic acid
- carrageenan
- ketamine
- doxycycline
- imatinib
- naltrexone
- tenecteplase
- bone marrow derived mesenchymal stem cells
- hydrocortisone
- ifx-1
- Filgrastim
- interferon alfa-n3
- ipratropium
- ivermectin
- metolazone
- nitazoxanide
- nitric oxide
- daclatasvir
- pneumococcal 13-valent conjugate vaccine
- ribavirin
- sarilumab
- cyclosporine
- cannabis
- sofosbuvir
- alteplase
- resveratrol
- spironolactone
- hepatitis a vaccine, inactivated
- +34 more
Phase 1 trials (15)
Organizations
Organization Involved with Phase 4 Indications (43)
- Bryn Mawr Hospital
- Baylor University
- Cedars-Sinai Medical Center
- University of London
- Harvard University
- Guangzhou Medical University
- Hospital do Coracao
- Hospital Moinhos de Vento
- Hospital Sirio-Libanes
- Providence Health & Services
- Radboud University
- Saint Francis Hospital and Medical Center
- Services Institute of Medical Sciences, Pakistan
- St. Francis Hospital, New York
- Sharp HealthCare
- Taoyuan General Hospital
- Texas A&M University
- University of Miami
- University of Athens
- West Virginia University
- Mayo Clinic
- Hellenic Institute for the Study of Sepsis
- Government of Pakistan
- Brazilian Clinical Research Institute
- University of Texas at Houston
- University of Barcelona
- Sharpe-Strumia Research Foundation
- Government of Taiwan
- Oswaldo Cruz Foundation
- Oslo Metropolitan University
- +13 more
Organization Involved with Phase 3 Indications (181)
- Regeneron
- Ache Laboratorios Farmaceuticos S.A.
- Daiichi Sankyo
- Toyama
- Roche
- Sanofi
- Novartis
- Apsen Farmaceutica S.A.
- Bharat Biotech International Limited
- Celltrion
- Cristália Produtos Químicos Farmacêuticos Ltda.
- CureVac AG
- Effice Servicios Para la Investigacion S.L.
- Hamad Medical Corporation
- Inovio Pharmaceuticals
- Novavax
- R-Pharm
- Rigel Pharmaceuticals
- Fundación Universitaria de Ciencias de la Salud
- Swiss National Science Foundation
- Telethon Kids Institute
- National Institutes of Health (NIH)
- Medical Research Council
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Unity Health Toronto
- Huazhong University of Science and Technology
- University of Manitoba
- Aligarh Muslim University
- CES University
- +151 more
Organization Involved with Phase 2 Indications (163)
- Hemispherx Biopharma
- Astellas
- Genentech
- Akebia Therapeutics
- Can-Fite BioPharma
- Faes Farma, S.A.
- GlaxoSmithKline
- Immune Design
- Karyopharm Therapeutics Inc
- Laboratorios Silanes S.A. de C.V.
- Lung Biotechnology PBC
- NeuroRx, Inc.
- Novoteris, LLC
- Verastem, Inc.
- Verona Pharma plc
- Altimmune, Inc.
- Apellis Pharmaceuticals, Inc.
- Boehringer Ingelheim
- The EMMES Corporation
- Fundación de investigación HM
- National Institute on Aging (NIA)
- University of Roma La Sapienza
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Aarhus University
- University of Pennsylvania
- Academic and Community Cancer Research United
- Cairo University
- Case Western Reserve University
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- +133 more
Organization Involved with Phase 1 Indications (28)
- Effector Therapeutics
- PT Bio Farma
- Vaxine Pty Ltd
- Daewoong Pharmaceutical Co. LTD.
- International Brain Research Foundation
- Oklahoma Medical Research Foundation
- Central Adelaide Local Health Network Incorporated
- Shahid Beheshti University of Medical Sciences
- Ascension Health
- Rockefeller University
- Dow University of Health Sciences
- Osaka University
- Stanford University
- University of Oklahoma
- University of California, Los Angeles
- Linear Clinical Research
- Medpace, Inc.
- Erciyes University
- Eijkman Institute for Molecular Biology, Jakarta, Indonesia
- Hampshire Hospitals NHS Foundation Trust
- Government of Saudi Arabia
- Healeon Medical Inc
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
- Rohto Pharmaceutical Co., Ltd.
- Rinati Skin, LLC
- Post-Graduate Medical Institute, Lahore
- Sironax USA, Inc.
- Pulmoquine Therapeutics, Inc
Organization Involved with Other Experimental Indications (29)
- Applied Biology, Inc.
- Ascletis Pharmaceuticals Co., Ltd.
- Qingfeng Pharmaceutical Group
- United States Army
- Cantonal Hosptal, Baselland
- Bay Area Retina Associates
- Instituto Nacional de Enfermedades Respiratorias
- Lancaster General Hospital
- Liverpool John Moores University
- Mazandaran University of Medical Sciences
- University of Nottingham
- Zhejiang University
- Bellerophon Therapeutics
- Federal University of Ceara
- University of Massachusetts
- University of Nice Sophia Antipolis
- University of Brescia
- National Council of Scientific and Technical Research, Argentina
- The Cleveland Clinic
- Ospedale di Bergamo
- University of Health Sciences Lahore
- Hospital de Clínicas "Jose de San Martin"
- Leeds Beckett University
- Hospital universitario del Vinalopo, Elche, Spain
- Bioithas SL
- Aferetica
- Centro de Excelencia en Productos y Procesos Córdoba
- Química Luar SRL
- Corpometria Institute